A238120 Stock Overview
Aligned Genetics, Inc., a biotech company, develops, manufactures, and sells imaging solutions for research institutions worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Aligned Genetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,485.00 |
| 52 Week High | ₩6,175.00 |
| 52 Week Low | ₩3,460.00 |
| Beta | 0.43 |
| 1 Month Change | 2.87% |
| 3 Month Change | 7.30% |
| 1 Year Change | 5.28% |
| 3 Year Change | 3.94% |
| 5 Year Change | 25.89% |
| Change since IPO | -15.97% |
Recent News & Updates
Shareholder Returns
| A238120 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 0.9% | -0.5% | -2.4% |
| 1Y | 5.3% | 1.4% | 1.9% |
Return vs Industry: A238120 exceeded the KR Life Sciences industry which returned 1.4% over the past year.
Return vs Market: A238120 exceeded the KR Market which returned 1.9% over the past year.
Price Volatility
| A238120 volatility | |
|---|---|
| A238120 Average Weekly Movement | 2.4% |
| Life Sciences Industry Average Movement | 7.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A238120 has not had significant price volatility in the past 3 months.
Volatility Over Time: A238120's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 61 | Yeon-Cheol Jung | alignedgenetics.com |
Aligned Genetics, Inc., a biotech company, develops, manufactures, and sells imaging solutions for research institutions worldwide. The company offers solutions for digital cell imaging, and tissue clearing and 3D imaging. It offers its solutions through distributors.
Aligned Genetics, Inc. Fundamentals Summary
| A238120 fundamental statistics | |
|---|---|
| Market cap | ₩64.49b |
| Earnings (TTM) | ₩3.24b |
| Revenue (TTM) | ₩15.21b |
19.9x
P/E Ratio4.2x
P/S RatioIs A238120 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A238120 income statement (TTM) | |
|---|---|
| Revenue | ₩15.21b |
| Cost of Revenue | ₩4.56b |
| Gross Profit | ₩10.66b |
| Other Expenses | ₩7.42b |
| Earnings | ₩3.24b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 225.05 |
| Gross Margin | 70.06% |
| Net Profit Margin | 21.27% |
| Debt/Equity Ratio | 12.5% |
How did A238120 perform over the long term?
See historical performance and comparison